A Stem Cell-Osteogenesis Axis in Malignant Breast Calcification: SQLE-Driven Reprogramming of Adipose-Derived Mesenchymal Stem Cells.
Wu Y., Zhang M., Li P., Chen F., Liu J., Hou Y.
Animal Study, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cell Rev Rep (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42014574
- DOI
- 10.1007/s12015-026-11124-6
Abstract (original English)
Background Breast calcifications are frequent mammographic findings and serve as critical indicators for the early detection of breast cancer. Breast calcifications are formed by a mineralization process considered passive deposits resulting from tissue necrosis, but accumulating evidence suggests that calcifications may instead arise from active stromal remodeling within the tumor microenvironment. Among the diverse stromal components, mesenchymal stem cells are particularly implicated in mediating mineralization processes. Adipose-derived mesenchymal stem cells (ADSCs), abundant in breast tissue and possessing strong osteogenic potential, could therefore play a key role in mineralization process. However, their contribution of ADSCs to malignant calcification formation remains poorly understood. Methods RNA sequencing was performed on malignant and benign calcified breast tissues to identify differentially expressed genes. Candidate genes were validated using public datasets, immunohistochemistry and survival analysis. ADSCs were isolated from patient breast tissue, phenotypically characterized and genetically modified to overexpress SQLE or HGD genes. Osteogenic differentiation was assessed by alkaline phosphatase activity, Alizarin Red S staining, qPCR and Western blot. In vivo effects were evaluated using a breast cancer xenograft model. Transcriptomic profiling, Seahorse
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.